Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3419973 | 0.89 | ALOX5 (0.50) | ALOX5ALDH1A1MAPK1MAPTLMNA | |
| SCHEMBL3421301 | 0.82 | RECQL (0.53) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL21810468 | 0.80 | MEN1 (0.72) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL3421530 | 0.79 | EGLN3 (0.55) | — | |
| SCHEMBL1717547 | 0.73 | RECQL (0.55) | ALOX5MEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL3423631 | 0.73 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPK1MAPT | |
| SCHEMBL15966795 | 0.72 | ALDH1A1 (0.67) | ALOX5ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL5529505 | 0.72 | ALDH1A1 (0.81) | ALOX5ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL19267278 | 0.72 | EGLN3 (0.46) | MEN1KMT2AALDH1A1LMNAKDM4E | |
| SCHEMBL3420090 | 0.72 | KDM4E (0.53) | ALOX5MEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-2037922-B9 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-11-13 | — | — | US | disclosed |
| US-8815884-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2037922-B1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-01-22 | — | — | EP | disclosed |
| US-8557834-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-8324208-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-05-06 | — | — | US | disclosed |
| EP-2037922-A2 | PROLYL HYDROXYLASE INHIBITORS | SmithKline Beecham Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024666-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20130072487-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20100113444-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1792/4885MEN1 3602/4885KMT2A 652/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20140336383-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
| US-20150315157-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | ALOX5 1559/4885MEN1 3831/4885KMT2A 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.